Phase II/III trial of Kevetrin for the treatment of ovarian cancer

Trial Profile

Phase II/III trial of Kevetrin for the treatment of ovarian cancer

Planning
Phase of Trial: Phase II/III

Latest Information Update: 16 Nov 2015

At a glance

  • Drugs Thioureidobutyronitrile (Primary) ; Docetaxel
  • Indications Ovarian cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Nov 2015 According to a Cellceutix media release, the company has chosen Docetaxel as the drug for the combination arm in this study.
    • 11 Nov 2015 According to Cellceutix media release, this trial will initiate in the first half of 2016.
    • 11 Nov 2015 According to Cellceutix media release, FDA has granted orphan drug designation to Kevetrin for ovarian cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top